Business & Finance

2 Penny Stocks That Are Expected to Grow

2 Penny Stocks That Are Expected to Grow #Penny #Stocks #Expected #Grow. Here is what we have for you today on TmZ Blog.

With all that’s been going on since the beginning of the pandemic, the state of the stock market is very unstable. This lack of stability has led to panic among some investors, while others perceive market volatility as a great buying opportunity.

In such conditions, people often buy penny stocks (stocks that are trading for less than $5), because if there’s even a small share price appreciation, the investors will get hefty profits.

So, how can we choose good penny stocks? Read on to find out about two promising stocks.

1. Xeris Pharmaceuticals (XERS)

Xeris Pharmaceuticals is based on an innovative technology platform that offers solutions for injectable and infusible therapies that simplify the process. Despite a serious sell-off at the end of June (at one point there was a loss coming in at 49%), its new $2.59 share price allows investors to go ahead and purchase these promising shares.

Analyst David Amsellem believes that is XERS underestimated as their innovative technologies are going to help adult patients with type 1 diabetes. Their cross-over study with 18 adult participants has proven that there was a 62% decrease in hyperglycemia in subcutaneous injections (SC) of XP-3924 (XERS innovation) comparing to injections of insulin alone. This gives the analytics and investors hope that the company’s future is going to be marked by rapid growth.

In the future Amsellem expects the company to look for a development partner in order to enhance the production capabilities of XERS and overall business growth. Amsellem thinks it’ll bring the shares to $11 price target (it 326% growth!), and other experts (from TipRanks, for example) agree.

2. Avinger (AVGR)

Jacob Delliou | All images and videos are copyrighted to their respective owners

Avinger is a company that designs medical devices for diagnosis and treatment of patients with Peripheral Artery Disease (PAD). The current price is only $0.29 apiece, which makes it a very promising investment.

Nathan Weinstein from Aegis Capital thinks that the company’s recent capital raise due to equity financing combined with their efforts to cut operating costs has significantly strengthened its position despite the challenges AVGR had to face due to coronavirus. The analyst believes that eventually there will be a return to normalcy in both patient volumes and ordering activity. 

Weinstein’s optimistic outlook implies a $1.40 price target, which is essentially a twelve-month gain of 368% compared to the current levels. It’s important to note that his opinion is shared by others, judging by the information from TipRanks. 

You May want to check our other related articles below and download our app.

About TmZ.NG

TmZ.NG is a modern digital platform for regular people who love breaking viral news and entertainment as it happens. You guessed it, a routine.

Our Blog Categories Include:

https://tmz.ng/category/leaked-videos/ |Leaked Videos
https://tmz.ng/category/biography/ |Biography
https://tmz.ng/category/business-finance/ |Business & Finance
https://tmz.ng/category/entertainment/ |Entertainment
https://tmz.ng/category/music/ |Music
https://tmz.ng/category/trending/ |Trending News
https://tmz.ng/category/video-and-movies/ |Videos And Movies
https://tmz.ng/category/viral/ |Viral News
https://tmz.ng/category/world/ |World News

Download Our APP

Download Our App For less Ads and more of Premium contents for free

Disclaimer For: 2 Penny Stocks That Are Expected to Grow

TMZ.NG believes the information on 2 Penny Stocks That Are Expected to Grow accessible via this website is accurate and trustworthy but makes no promise regarding its timeliness, completeness, or correctness. TMZ.NG isn't a broker. We don't offer individualized investment advice. This website's information is subject to change. This website's content may become old, incomplete, or wrong. We may update obsolete, incomplete, or erroneous information, but aren't required to.

It would be best if you never made an ICO, IEO, or other investment decision based on the material on this website, nor should you consider it financial advice. If you need investing advice on an ICO, IEO, or other investment, visit a licensed advisor. We don't take payment to analyze or report on ICOs, IEOs, cryptocurrencies, currencies, tokenized sales, stocks, or commodities.

Show More

Xam Xin

I'm Olamilekan Atolagbe, I'm fueled by my passion for understanding the nuances of cross-cultural publishing. I consider myself a "forever student," eager to both build on my academic foundations in programming and computer science and stay in tune with the latest content publishing strategies through continued coursework and professional development.

Related Articles

Back to top button

AdBlocker Detected

Please Disable your AdBlocker to Continue using our site. Support us by enabling ads